Seelos Therapeutics EBITDA 2010-2022 | SEEL
Seelos Therapeutics ebitda from 2010 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Seelos Therapeutics Annual EBITDA
(Millions of US $) |
| 2021 |
$-60 |
| 2020 |
$-19 |
| 2019 |
$-30 |
| 2018 |
$-3 |
| 2017 |
$-11 |
| 2016 |
$-14 |
| 2015 |
$-21 |
| 2014 |
$-22 |
| 2013 |
$-17 |
| 2012 |
$-17 |
| 2011 |
$-18 |
| 2010 |
$-10 |
| 2009 |
$26 |
Seelos Therapeutics Quarterly EBITDA
(Millions of US $) |
| 2022-03-31 |
$-14 |
| 2021-12-31 |
$-27 |
| 2021-09-30 |
$-11 |
| 2021-06-30 |
$-6 |
| 2021-03-31 |
$-16 |
| 2020-12-31 |
$-6 |
| 2020-09-30 |
$-4 |
| 2020-06-30 |
$-3 |
| 2020-03-31 |
$-6 |
| 2019-12-31 |
$-10 |
| 2019-09-30 |
$-4 |
| 2019-06-30 |
$-3 |
| 2019-03-31 |
$-12 |
| 2018-12-31 |
$-1 |
| 2018-09-30 |
$-1 |
| 2018-06-30 |
$-0 |
| 2018-03-31 |
$-1 |
| 2017-12-31 |
$-3 |
| 2017-09-30 |
$-4 |
| 2017-06-30 |
$-2 |
| 2017-03-31 |
$-2 |
| 2016-12-31 |
$-3 |
| 2016-09-30 |
$-2 |
| 2016-06-30 |
$-5 |
| 2016-03-31 |
$-5 |
| 2015-12-31 |
$-3 |
| 2015-09-30 |
$-6 |
| 2015-06-30 |
$-6 |
| 2015-03-31 |
$-6 |
| 2014-12-31 |
$-17 |
| 2014-09-30 |
$-3 |
| 2014-06-30 |
$1 |
| 2014-03-31 |
$-4 |
| 2013-12-31 |
$-4 |
| 2013-09-30 |
$-3 |
| 2013-06-30 |
$-4 |
| 2013-03-31 |
$-6 |
| 2012-12-31 |
$-7 |
| 2012-09-30 |
$-2 |
| 2012-06-30 |
$-4 |
| 2012-03-31 |
$-4 |
| 2011-12-31 |
$-4 |
| 2011-09-30 |
$-2 |
| 2011-06-30 |
$-8 |
| 2011-03-31 |
$-3 |
| 2010-12-31 |
$-18 |
| 2010-09-30 |
$1 |
| 2010-06-30 |
$-2 |
| 2010-03-31 |
$-2 |
| 2009-12-31 |
$27 |
| 2009-09-30 |
$-1 |
| 2009-06-30 |
$-1 |
| 2009-03-31 |
$1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.072B |
$0.000B |
|
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
|
